) in a report released today. In the report, JP Morgan was positive in its assessment of the company. JP Morgan writes, "Omnicare views specialty as a core competency and a key growth driver going forward. The company noted that it has a 360 degree view of the industry, serving patients, providers, caregivers, nurses, physicians, and manufacturers, and offers multiple growth platforms, including specialty pharmacy, reimbursement support hub programs, patient assistance programs, third-party logistics, and patient management programs for end of life care." JP Morgan currently has an Overweight rating on JP Morgan and a price target of $34. Shares of OCR closed at $31.45 on Thursday.